On October 25, 2025, Phathom Pharmaceuticals announced that analysis from its Phase 3 trial of VOQUEZNA revealed significant relief of nighttime GERD symptoms, reporting 59.9% heartburn-free nights for the 10 mg dose and 56.4% for the 20 mg dose compared to 43.3% for placebo.